Investigators Provide Perspectives on the Best-Practice Management of Ovarian Cancer — Symposium Video Proceedings

Faculty

TARGET AUDIENCE
This program is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of ovarian cancer.

LEARNING OBJECTIVES

• Understand available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced OC, and appropriately counsel patients regarding personalized treatment recommendations.
• Appraise biological and patient- and treatment-related factors to individualize the selection and sequencing of therapy for platinum-sensitive and platinum-resistant recurrent OC.
• Recognize the rationale for targeting FRα in OC, and understand the mechanism of action of and available research findings with FRα-directed antibody-drug conjugates.
• Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with platinum-resistant OC, and consider the current role of this novel therapeutic strategy.
• Understand the biological justification for the evaluation of selective glucocorticoid receptor modulators in combination with chemotherapy for patients with platinum-resistant OC, and recall available and emerging Phase III findings with this novel approach.
• Recognize adverse events associated with therapeutic approaches commonly employed for OC, and implement strategies to educate patients and manage complications.
• Describe the scientific justification for, published research data with and current research studies of novel agents and strategies for OC, and effectively prioritize clinical trial opportunities for eligible patients.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and post-test, enables the participant to earn up to 1.75 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology. 

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.. 

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/SGO26Ovarian/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Nicoletta Colombo, MD
Director, Gynecologic Oncology Program
European Institute of Oncology IRCCS
Milan, Italy

Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, BioNTech SE, Corcept Therapeutics Inc, Eisai Inc, Gilead Sciences Inc, GSK, ImmunoGen Inc, Lilly, MSD, Novocure Inc, Regeneron Pharmaceuticals Inc, Seagen Inc; Data and Safety Monitoring Boards/Committees: Incyte Corporation; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Eisai Inc, GSK, MSD.

Gottfried E Konecny, MD
Professor of Medicine and Ob/Gyn
Director, Medical Gynecologic Oncology
Division of Hematology and Oncology
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California

No relevant financial relationships to disclose.

Alexander B Olawaiye, MD 
Professor
Department of Obstetrics, Gynecology and Reproductive Sciences
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, GSK, Lilly, Merck; Consulting Agreements: Corcept Therapeutics Inc; Speakers Bureaus: Foundation Medicine.

CONSULTING CLINICAL INVESTIGATORS
Professor Jonathan A Ledermann — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Flindr, GSK, ImmunoGen Inc, MSD, Novocure Inc; Consulting Agreements: AbbVie Inc, GSK; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Sutro Biopharma, Zentalis Pharmaceuticals; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, GSK, Medison Pharmaceuticals, MSD. Ursula Matulonis, MD — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Day One Biopharmaceuticals, GSK, NextCure, Novartis, Tango Therapeutics; Consulting Agreements: Whitehawk Therapeutics; Data and Safety Monitoring Boards/Committees: Daiichi Sankyo Inc, MacroGenics Inc, Mural Oncology Inc, Symphogen A/S. Angeles Alvarez Secord, MD, MHSc — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Foundation Medicine, Genmab US Inc, Gilead Sciences Inc, GSK, HistoSonics, Medtronic Inc, Merck; Clinical Trial Steering Committees: Genmab US Inc, OncoQuest Inc; Consulting Agreements: GSK, Merck; Contracted Research: AbbVie Inc, Aravive Inc, AstraZeneca Pharmaceuticals LP, Canaria Bio Inc, Daiichi Sankyo Inc, Ellipses Pharma, Genentech, a member of the Roche Group, Genmab US Inc, GSK, ImmunoGen Inc, Karyopharm Therapeutics, Merck, Mersana Therapeutics Inc, Myriad Genetic Laboratories Inc, OncoQuest Inc, TORL BioTherapeutics, Zentalis Pharmaceuticals; Stock Options/Stock — Public Companies: Stock in Amgen Inc and Johnson & Johnson, divested in June 2024.

MODERATOR
Shannon N Westin, MD, MPH, FASCO, FACOG
Professor
Medical Director, Gynecologic Oncology Center
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, GSK, Immunocore, ImmunoGen Inc, Incyte Corporation, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mereo BioPharma, NGM Biopharmaceuticals, Nuvectis Pharma Inc, Ottimo Pharma, Pfizer Inc, pharmaand GmbH, PMV Pharma, Seagen Inc, Verastem Inc, Zentalis Pharmaceuticals, ZielBio; Contracted Research: AstraZeneca Pharmaceuticals LP, Avenge Bio, Bayer HealthCare Pharmaceuticals, Bio-Path Holdings Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, GSK, Jazz Pharmaceuticals, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mereo BioPharma, Novartis, Nuvectis Pharma Inc, pharmaand GmbH, Pfizer Inc, Verastem Inc, Zentalis Pharmaceuticals.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, and Merck.

Release date: May 2026
Expiration date: May 2027

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Prof Colombo

Bradley W et al. Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1. SGO 2021;Abstract 10520.

DiSilvestro P et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1/GOG 3004 trial. J Clin Oncol 2023;41(3):609-17. Abstract

González-Martín A et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019;381(25):2391-402. Abstract

Harter P et al. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. Gynecol Oncol 2022;164(2):254-64. Abstract

Hettle R et al. Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer. Ther Adv Med Oncol 2021:13:17588359211049639. Abstract

Konstantinopoulos PA et al. Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov 2015;5(11):1137-54. Abstract

Monk BJ et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: Final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann Oncol 2024;35(11):981-92. Abstract

Monk BJ et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol 2022;40(34):3952-64. Abstract

O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell 2015;60(4):547-60. Abstract

Ray-Coquard I et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: Final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol 2023;34(8):681-92. Abstract

Ray-Coquard I et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 2019;381(25):2416-28. Abstract

Saevets V et al. MONO-OLA1: A randomized, phase III study of olaparib maintenance monotherapy in patients with BRCA wild-type advanced ovarian cancer following response to first-line platinum-based chemotherapy. SGO 2022;Abstract 334.

Vergote I et al. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. Eur J Cancer 2021;157:415-23. Abstract

Dr Westin

Alvarez Secord A et al. The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: The single-arm phase II PICCOLO trial. Ann Oncol 2025;36(3):321-30. Abstract

Lee EK et al. A phase I/II study of rinatabart sesutecan (Rina-S) in patients with advanced ovarian or endometrial cancer. ESMO 2024;Abstract 719MO.

Matulonis UA et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: Results from the SORAYA study.J Clin Oncol 2023;41(13):2436-45. Abstract

Moore KN et al. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. N Engl J Med 2023;389(23):2162-74. Abstract

Moore KN et al. Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator’s choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. ASCO 2023;Abstract LBA5507. 

Oaknin A et al. Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort. ASCO 2023;Abstract 5508. 

O’Malley DM et al. Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer. Future Oncol 2024;20(32):2423-36. Abstract

Ray-Coquard IL et al. Raludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): Primary analysis of the phase II dose-optimization part of REJOICE-Ovarian01. ESMO 2025;Abstract LBA42.

Shapira-Frommer R et al. Initial results from a first-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients (pts) with platinum-resistant recurrent ovarian cancer (PRROC). ESMO 2024;Abstract 754P.

Dr Olawaiye

Colombo N et al. Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomized double-blind phase III ENGOT-ov65/KEYNOTE-B96 study. ESMO 2025;Abstract LBA3. 

Olawaiye A et al. Final overall survival (OS) results from the phase 3 ROSELLA trial: Relacorilant plus nab-paclitaxel vs nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (PROC) (GOG-3073, ENGOT-ov72, APGOT-Ov10, and LACOG-0223). SGO 2026;Abstract S451. 

Olawaiye A et al. ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72). ASCO 2025;Abstract LBA5507. 

Olawaiye AB et al. Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): An open-label, randomised, controlled, phase 3 trial. Lancet 2025;405(10496):P2205-16. Abstract

Dr Konecny

Tsao L-C et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat Commun 2025;16(1):3167. Abstract

Wei Q et al. Perivascular niche-resident alveolar macrophages promote interstitial pneumonitis related to trastuzumab deruxtecan treatment. Cancer Res 2025; 85(11):2081-99. Abstract